UK-based Medtech startup Amber Therapeutics has announced the successful closing of its series A financing round, securing $100 million to advance Amber-UI, a breakthrough therapy for women suffering from mixed urinary incontinence (MUI).
The financing, which is one of Europe’s series A rounds for a medical technology company, featured participation from leading healthcare and tech companies from Europe and the US.
The funds were raised by a syndicate of new investors led by New Enterprise Associates (NEA), with a significant contribution from Intuitive Ventures, F-Prime Capital, and Lightstone Ventures. Existing Investors, including 8VC and Oxford Science Enterprises (OSE), also participated in the landmark funding round.
Securing such significant funding from leading US and UK investors validates the therapeutic value of Amber Therapeutics’ new treatment proposition and the confidence in the team that developed it.
With the new funding, Amber Therapeutics plans to execute its planned pilot studies in Europe and a pivotal clinical trial of Amber-UI in the US for FDA approval, making the breakthrough therapy available for millions of women struggling with mixed urinary incontinence.
Amber-UI
Amber-UI is the world’s first adaptive and fully implantable neuromodulation therapy ever developed for women MUI in the field of clinical development. Deployed through a minimally invasive surgical procedure, Amber-UI targets the pudendal nerve to treat urinary incontinence (UI), a condition known to affect millions of women globally.
Many women struggling with the condition experience urge incontinence, which manifests through urgent and uncontrollable bladder leaks, and stress incontinence—bladder leaks during exertion or physical activities. So far, there’s no single treatment that can alleviate these symptoms, making the new therapy a game-changer for the treatment of patients experiencing MUI symptoms.
Amber-UI runs on the company’s adaptive neuromodulation system (Picostim System), which can stimulate and sense physiological responses configured based on an individual’s needs and respond to different events dynamically. When in place, Umber-UI regulates the user’s urge, voiding the bladder and augmenting resistance to urine leakage during lifting or coughing, restoring normal bladder function.
The therapy has shown promising preliminary results during its first-ever in-human study (AURA-2), the company announced in February 2024. The study results confirmed the feasibility and safety of the adaptive therapy and surgical procedure, as well as a strong efficacy signal.
